Optimizing Atogepant Dosage for Migraine Prevention

Research Summary

Researchers developed a population pharmacokinetic model for atogepant, a drug intended to prevent migraines, using data from multiple clinical studies. This model, detailed in the journal Clinical Pharmacokinetics, supports dosage selection for patients with either episodic or chronic migraines. The study found that factors such as formulation, dose, food intake, and liver function significantly affect the drug's pharmacokinetics. Additionally, severe hepatic impairment and certain drug interactions notably alter atogepant's clearance rates. However, age, sex, race, and the use of specific medications do not necessitate dose adjustments. The model aids healthcare providers and regulatory agencies in making informed decisions about atogepant treatment.

Study Details

📄 Title: Population Pharmacokinetics of Atogepant for the Prevention of Migraine.

👥 Research Team: Schlachter L et al.

📚 Published In: Clin Pharmacokinet

📅 Publication Date: 2025 Nov 12

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.